NCT04093362: A reported trial by Taiho Oncology, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04093362 |
|---|---|
| Title | A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 6, 2021 |
| Completion date | April 22, 2024 |
| Required reporting date | April 22, 2025, midnight |
| Actual reporting date | Jan. 15, 2025 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |